Trial Profile
A Retrospective, Monocentric, Case Series Study Assessing Reticular Pseudodrusen (RPD) As A Potential Baseline Factor Predictive Of A Poor 1-Year Response To Intravitreal Ranibizumab In Consecutive Naive Neovascular Age-Related Macular Degeneration Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 16 May 2017 New trial record